Drug intelligence / Profile preview

YN202

Development stage: Unknown
Lead developer: Guangzhou Yinnuo Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

YN202 is an investigational drug candidate being developed by Guangzhou Yinnuo Pharmaceutical (also known as Innogen Pharmaceutical) for the treatment of obesity and overweight. It functions by targeting the growth hormone secretagogue receptor (GHS-R), which is the primary receptor for ghrelin, a hormone that plays a central role in appetite stimulation and energy homeostasis. By modulating GHS-R activity, YN202 aims to regulate metabolic processes and body weight. As of the latest pipeline updates, the drug is in the preclinical stage of development.

Targets

GHSR (Growth hormone secretagogue receptor)

Beyond the preview

Go deeper on YN202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YN202.

Explore the full profile